Information de reference pour ce titreAccession Number: | 00003017-199909070-00018.
|
Author: | Grundy, Scott M. MD, PhD, Chair; Benjamin, Ivor J. MD; Burke, Gregory L. MD; Chait, Alan MD; Eckel, Robert H. MD; Howard, Barbara V. PhD; Mitch, William MD; Smith, Sidney C. Jr, MD; Sowers, James R. MD
|
Institution: | This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in April 1999. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0175. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or e-mail [email protected]. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400. (Circulation. 1999;100:1134-1146.).
|
Title: | Diabetes and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association.[Miscellaneous Article]
|
Source: | Circulation. 100(10):1134-1146, September 7, 1999.
|
References: | 1. Gerick JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
2. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol. 1997;24:782-784.
3. Muller DC, Elahi D, Tobin JD, Andres R. The effect of age on insulin resistance and secretion: a review. Semin Nephrol. 1996;16:289-298.
4. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE. Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol. 1998;275:E785-E791.
5. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855-1861.
6. Humphriss DB, Stewart MW, Berrish TS, Barriocanal LA, Trajano LR, Ashworth LA, Brown MD, Miller M, Avery PJ, Alberti KG, Walker M. Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia. 1997;40:1185-1190.
7. Hopkins PN, Hunt SC, Wu LL, Williams GH, Williams RR. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Curr Opin Lipidol. 1996;7:241-253.
8. Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ. Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am J Epidemiol. 1998;148:869-878.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1202.
10. Stern MP. Impaired glucose tolerance: risk factor or diagnostic category. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:467-474.
11. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
12. Unger RH, Foster DW. Diabetes mellitus. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders Co; 1998:973-1059.
13. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM: gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16:720-726.
14. Diabetes Statistics. National Diabetes Information Clearinghouse. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, NIH publication 99-3926. 1999.
15. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998.
16. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; 1996.
17. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125:221-232.
18. Lindeman RD, Romero LJ, Hundley R, Allen AS, Liang HC, Baumgartner RN, Koehler KM, Schade DS, Garry PJ. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care. 1998;21:959-966.
19. Cappuccio FP, Cook DG, Atkinson RW, Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart. 1997;78:555-563.
20. Prevalence of diagnosed diabetes among American Indians/Alaskan Natives-United States, 1996. MMWR Morb Mortal Wkly Rep. 1998;47:901-904.
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
22. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis. 1998;32:S89-S100.
23. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol. 1998;82:30T-36T.
24. Brezinka V, Padmos I. Coronary heart disease risk factors in women. Eur Heart J. 1994;15:1571-1584.
25. Geiss LS, Herman WH, Smith PJ, National Diabetes Data Group. Diabetes in America. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:233-257.
26. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al, the MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol. 1989;14:49-57.
27. Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction: interaction of diabetes with other preinfarction risk factors. Diabetes. 1989;38:350-357.
28. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 1984;54:718-721.
29. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM: a population-based study. Diabetes Care. 1993;16:1022-1025.
30. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595-602.
31. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. Evidence of cardiomyopathy in familial diabetes mellitus. J Clin Invest. 1977;60:884-899.
32. Regan TJ. Congestive heart failure in the diabetic. Annu Rev Med. 1983;34:161-168.
33. Ettinger PO, Regan TJ. Cardiac disease in diabetes. Postgrad Med. 1989;85:229-232.
34. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990;82:848-855.
35. Gotzsche O, Darwish A, Gotzsche L, Hansen LP, Sorensen KE. Incipient cardiomyopathy in young insulin-dependent diabetic patients: a seven-year prospective Doppler echocardiographic study. Diabet Med. 1996;13:834-840.
36. Spector KS. Diabetic cardiomyopathy. Clin Cardiol. 1998;21:885-887.
37. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem. 1998;180:59-64.
38. Klimt CR, Knatterud GI, Meinert CL, Prout TE, University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes. 1970;19(suppl):789-830.
39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
40. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care. 1993;16:434-444.
41. Bell DSH. Stroke in the diabetic patient. Diabetes Care. 1994;17:213-219.
42. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG, Atherosclerosis Risk in Communities Study Investigators. Relation of carotid artery wall thickness in diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25:66-73.
43. O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK Jr, Bommer W, Price TR, Gardin JM, Savage PJ. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992;23:1752-1760.
44. Kuller LH, National Diabetes Data Group. Stroke and diabetes. In: Diabetes in America. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:449-456.
45. Nelson RG, Knowler WC, Pettitt JD, Bennett PH, National Diabetes Data Group. Kidney diseases in diabetes. In: Diabetes in America. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:349-400.
46. Mogensen CE, Christensen CK, Vittinghus E. The stages of diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32:64-78.
47. US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1994.
48. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and types of diabetes. N Engl J Med. 1989;321:1074-1079.
49. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982;306:1276-1279.
50. Stephens GW, Gillaspy JA, Clyne D, Mejia A, Pollak VE. Racial differences in the incidence of end-stage renal disease in types I and II diabetes mellitus. Am J Kidney Dis. 1990;15:562-567.
51. Lopes AA, Port FK, James SA, Agodoa L. The excess risk of treated end-stage renal disease in blacks in the United States. J Am Soc Nephrol. 1993;3:1961-1971.
52. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC. Effect of proteinuria on mortality in NIDDM. Diabetes. 1988;37:1499-1504.
53. McMillan MA, Briggs JD, Junor BJ. Outcome of renal replacement treatment in patients with diabetes mellitus. BMJ. 1990;301:540-544.
54. Hirschl MM, Heinz G, Sunder-Plassmann G, Derfler K. Renal replacement therapy in type 2 diabetic patients: 10 years' experience. Am J Kidney Dis. 1992;20:564-568.
55. Rischen-Vos J, van der Woude FJ, Tegzess AM, Zwinderman AH, Gooszen HC, van den Akker PJ, van Es LA. Increased morbidity and mortality in patients with diabetes mellitus after kidney transplantation as compared with non-diabetic patients. Nephrol Dial Transplant. 1992;7:433-437.
56. ADA Consensus Panel. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes: American Diabetes Association. Diabetes Care. 1989;12:573-579.
57. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
58. Hammes H-P, Brownlee M. Advanced glycation end products and pathogenesis of diabetic complications. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: Lippincott-Raven Publishers: 1996:810-815.
59. Nadler JL, Winer L. Free radicals, nitric oxide, and diabetic complications. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:840-847.
60. Reaven GM. Insulin resistance and its consequences: non-insulin-dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:509-519.
61. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
62. Bogardus C, Lillioja S, Mott D, Reaven GR, Kashiwagi A, Foley JE. Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians. J Clin Invest. 1984;73:800-805.
63. Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K, Rothman DL, Shulman GI. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med. 1996;335:1357-1362.
64. Rowe JW, Minaker KL, Pallota JA, Flier JS. Characterization of the insulin resistance of aging. J Clin. Invest. 1983;71:1581-1587.
65. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
66. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
67. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett KC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
68. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
69. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 1996;7:167-171.
70. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.
71. Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. J Intern Med. 1998;243:265-274.
72. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
73. Nelson RG, Pettitt DJ, Baird HR, Charles MA, Liu QZ, Bennett PH, Knowler WC. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1993;36:998-1001.
74. Edelson GW, Sowers JR. Insulin resistance in hypertension: a focused review. Am J Med Sci. 1993;306:345-347.
75. Sowers JR. Insulin resistance and hypertension. Mol Cell Endocrinol. 1990;74:C87-C89.
76. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
77. Haffner SM. Impaired glucose tolerance, insulin resistance, and cardiovascular disease. Diabet Med. 1997;14:S12-S18.
78. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis. 1998;137:S65-S73.
79. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome: a population-based study. Diabetes Care. 1998;21:649-654.
80. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol. 1998;18:258-264.
81. Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia. 1998;41:609-622.
82. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
83. Grundy SM, Wilhelmsen L, Rose G, Campbell RWF, Assman G. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J. 1990;11:462-471.
84. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York, NY: McGraw Hill; 1985:1981-2030.
85. National Center for Health Statistics. Plan and operation of the second national health interview survey 1976-1980. In: Vital and Health Statistics. Washington, DC: US Government Printing Office; Ser. 1, No. 15, DHHS Publication 81-1317, 1981.
86. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
87. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
88. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
89. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
90. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
91. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ. 1988;296:156-160.
92. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, Dejgaard A, Lauritzen M, Lauritzen E, Hougaard P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:655-661.
93. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 1992;41:836-839.
94. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
95. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736-741.
96. Microalbuminuria Collaborative Study Group United Kingdom. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ. 1993;306:1235-1239.
97. Nelson RG, Knowler WC, McCance DR, Sievers ML, Pettitt DJ, Charles MA, Hanson RL, Liu QZ, Bennett PH. Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia. 1993;36:1087-1093.
98. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-581.
99. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
100. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med. 1993;118:129-138.
101. Nesto RW, Phillips RT. Asymptomatic myocardial ischemia in diabetic patients. Am J Med. 1986;80:40-47.
102. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD, Winters WL Jr, Yanowitz FG, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Exercise Testing). Circulation. 1997;96:345-354.
103. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, et al. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
104. Ockene IS, Miller NH, American Heart Association Task Force on Risk Reduction. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation. 1998;96:3243-3247.
105. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program; 1997.
106. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
107. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
108. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-38.
109. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med. 1998;129:38-41.
110. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:1080.
111. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20:736-744.
112. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, Heart and Estrogen/Progestin Replacement Study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
113. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients the National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation. 1996;94:1818-1825.
114. Herlitz J, Wognsen GB, Emanuelsson H, Haglid M, Karlson BW, Karlsson T, Albertsson P, Westberg S. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care. 1996;19:698-703.
115. Gum PA, O'Keefe JH Jr, Borkon AM, Spertus JA, Bateman TM, McGraw JP, Sherwani K, Vacck J, McCallister BD. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation. 1997;96(suppl II):II-7-II-10.
116. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761-1769.
117. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation. 1998;97:1876-1887.
118. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care. 1997;20:518-520.
119. Haffner SM. Management of dyslipidemia in adults with diabetes: technical review. Diabetes Care. 1998;21:160-178.
120. American Diabetes Association. Management of dyslipidemia in adults with diabetes. American Diabetes Association: Clinical Practice Recommendations 1999. Diabetes Care. 1999;22:556-559.
|
Language: | English.
|
Document Type: | Aha Scientific Statement.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0009-7322
|
NLM Journal Code: | daw, 0147763
|
Annotation(s) | |
|
|